Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children

AIDS

Volumn 14, Issue 12, 2000, Pages 1866-1868

  Wintergerst, Uwe ^a   Engelhorn, Carolin ^a   Kurowski, Michael ^b   Hoffmann, Florian ^a   Notheis, Gundula ^a   Belohradsky, Bernd H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Vivantes Auguste Viktoria Klinikum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; CYTOCHROME P450; DELAVIRDINE; EFAVIRENZ; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; CARBAMATES; CHILD; CHILD, PRESCHOOL; DELAVIRDINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SULFONAMIDES; TIME FACTORS;

EID: 0033823238     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200008180-00030     Document Type: Article

References (16)

1. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
2. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz inpatients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
3. A 24 week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
4. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy
5. Indinavir concentrations and antiviral effect
6. A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity
7. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir
8. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
9. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults
10. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents
11. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
12. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A
13. Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P450 3A
14. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers